Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus

Xu, Li; Jiao, Zheng; Liu, Feiyan; Qiu, Xiaoyan; Ji, Li; Zhang, Ming

doi:10.1097/ftd.0000000000000533

Cited by 4 publications

(3 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MLR is a straightforward technique available with every statistics software program, and the resulting equations can be easily implemented in a spreadsheet. Although for MMF most LSSs of 2-3 time points within the first 3 hours postdose were efficient to approximate the full AUC, 9 for EC-MPS it was not straightforward 148 : 3 blood samples were rarely sufficient 142,146 but more often 4 and up to 8 were required, 149,150 over a generally longer period of 4-9 hours after dosing 146,148,[150][151][152] because of the highly variable absorption of the drug and day-to-day fluctuation in enterohepatic cycling of MPA. 9 Importantly, Hougardy et al 143 reported that MPA AUC estimation using a 4-point LSS failed in .30% of patients on EC-MPS, especially when C0 was the highest concentration measured.…”

Section: Limited Sampling Strategiesmentioning

confidence: 99%

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Bergan¹,

Brunet²,

Hesselink³

et al. 2021

Therapeutic Drug Monitoring

116

237

View full text Add to dashboard Cite

When mycophenolic acid (MPA) was originally marketed for immunosuppressive therapy, fixed doses were recommended by the manufacturer. Awareness of the potential for a more personalized dosing has led to development of methods to estimate MPA area under the curve based on the measurement of drug concentrations in only a few samples. This approach is feasible in the clinical routine and has proven successful in terms of correlation with outcome. However, the search for superior correlates has continued, and numerous studies in search of biomarkers that could better predict the perfect dosage for the individual patient have been published. As it was considered timely for an updated and

show abstract

Section: Limited Sampling Strategiesmentioning

confidence: 99%

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Bergan¹,

Brunet²,

Hesselink³

et al. 2021

Therapeutic Drug Monitoring

116

237

View full text Add to dashboard Cite

show abstract

“…Next, the |MPE| percentages within 15% (F 15 ), 20% (F 20 ), and 25% (F 25 ) were calculated. The model was considered clinically acceptable if it yielded an MPE ≤ ±15%, MAE ≤ 30%, F 15 > 40%, F 20 > 45%, and F 25 > 50% [33].…”

Section: Pharmacokinetic Analysismentioning

confidence: 99%

Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation

Cui

Yan

Zhu

et al. 2023

JPM

Self Cite

View full text Add to dashboard Cite

Background: Although tacrolimus has been widely used in patients undergoing lung transplantation, few studies have reported the pharmacokinetics of tacrolimus in Chinese patients after lung transplantation. Thus, we aimed to investigate the pharmacokinetics and influential factors in this patient cohort in the early stage after lung transplantation. Methods: We enrolled 14 adult lung transplant recipients who were treated with tacrolimus and then intensively collected blood samples within a 12-h dosing interval. The pharmacokinetic parameters of tacrolimus were calculated using non-compartmental analysis, and the influence of pathophysiological characteristics and CYP3A5*3 and CYP3A4*1G genotypes on the pharmacokinetics of tacrolimus was assessed. Using linear regression analysis, we investigated the correlation between tacrolimus concentration at different sampling points and measured the area under the time-concentration curve (AUC0–12h). Results: Geometric mean of apparent clearance (CL/F) was 18.13 ± 1.65 L/h in non-CYP3A5*3/*3 carriers, five times higher than that in CYP3A5*3/*3 carriers (p < 0.001). Furthermore, the tacrolimus concentration 4 h after administration had the strongest correlation with AUC0–12h (R2 = 0.979). Conclusion: The pharmacokinetics of tacrolimus varied largely between patients during the early stage post-transplantation, which could be partially explained by CYP3A5*3 genetic polymorphisms.

show abstract

“…The predictive performance was evaluated using the coe cients of determination (R 2 ), mean prediction error (MPE), and mean absolute prediction error (MAE), which were described by Sheiner and Beal 33 |MPE| percentages within 15% (F15), 20% (F20), and 25% (F25) were calculated. The model is considered clinically acceptable if it yields an MPE ≤ ± 15%, MAE ≤ ± 30%, F15 > 40%, F20 > 45%, and F25 > 50% 34 .…”

Section: Pharmacokinetic Analysismentioning

confidence: 99%

Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients Receiving Voriconazole During the Early Stage Post-Lung Transplantation

Cui

Zhu

Yan

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Although tacrolimus has been widely used in patients undergoing lung transplantation, few studies have reported the pharmacokinetics of tacrolimus in Chinese patients after lung transplantation. Thus, we aimed to investigate its pharmacokinetics and influential factors in this patient cohort in the early stage after lung transplantation. We enrolled 14 lung transplant recipients who were treated with tacrolimus and voriconazole. We then collected intensive blood samples within a 12-hour dosing interval and analysed them via liquid chromatography-mass spectrometry. The pharmacokinetic parameters of tacrolimus were calculated using non-compartmental analysis, and the influence of physio-pathological characteristics and CYP3A5*3 and CYP3A4*1G genotypes on the pharmacokinetics of tacrolimus was assessed. Using linear regression analysis, we then investigated the correlation between tacrolimus concentration at different sampling points and measured the area under the curve (AUC0 − 12h). Our results showed a mean apparent clearance (CL/F) rate of 14.2 ± 11.0 L/h, with CYP3A5*1 carriers having a CL/F rate five times higher than non-carriers (P < 0.001). Furthermore, tacrolimus concentration 4 h after the administration had the strongest correlation with AUC0 − 12h (R2 = 0.979). In summary, tacrolimus pharmacokinetics varied largely between patients during the early-stage post-lung transplantation, which could be partly explained by CYP3A5 genetic polymorphisms. Therefore, it is crucial to closely monitor tacrolimus blood concentration in the early stages after lung transplantation.

show abstract

Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus

Abstract: The pharmacokinetic profile of total and free MPA and its main metabolite MPAG was examined in Chinese adult renal transplant patients receiving EC-MPS. The use of LSS to estimate individual free and total MPA exposure could be useful in optimizing patient care.

Cited by 4 publications

References 79 publications

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology

Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients during the Early Stages Post-Lung Transplantation

Pharmacokinetic Evaluation of Tacrolimus in Chinese Adult Patients Receiving Voriconazole During the Early Stage Post-Lung Transplantation

Contact Info

Product

Resources

About